Pipeline

Home » Pipeline

Bioniz Pipeline of Multi-Cytokine Inhibitors

Prior to Bioniz, multi-cytokine inhibition has been attempted with bi-specific or multi-specific antibodies and JAK inhibitors, both of which fundamentally lack the ability to selectively inhibit specific cytokines. Bioniz’s approach is to apply rationally-designed peptides, each of which are capable, as a single therapeutic agent, of blocking multiple disease-driving cytokines that utilize a common receptor, without interfering with the rest of the healthy cytokine network. Peptides provide the high-level specificity of an antibody, due to their protein-protein interaction, but are small enough to block only certain pockets on the common receptor thereby leaving the receptor available for non-targeted cytokine signaling.

BNZ-1

Cutaneous T-Cell Lymphoma (CTCL)

Title

90%

BNZ-1

Alopecia Areata (AA)

Title

65%

BNZ-2

GI Inflammation
(Indications TBD)

Title

40%

BNZ-3

(oral) GI Inflammation

Title

15%

Cytokine Activators

Undisclosed

Title

15%

BNZ-1 (IL-2/9/15 Inhibitor) for Cutaneous T-Cell Lymphoma (CTCL)

Cutaneous T-cell lymphoma (CTCL) is a rare, progressive form of non-Hodgkin’s Lymphoma (NHL) characterized by localization of neoplastic T lymphocytes to the skin. Accounting for 4% of non-Hodgkin’s lymphomas, CTCL is generally considered incurable with currently available therapies, which exhibit suboptimal disease control. Consequently patients often cycle through multiple therapies.

BNZ-1 is a selective inhibitor of three members of the IL-2 family: IL-2, IL-9, and IL-15. The profile of BNZ-1 is promising as a long-term therapy capable of transforming the standard of care in CTCL as data implicates the dysregulation of IL-2/IL-9/IL-15 as responsible for disease pathology. Bioniz conducted a Phase 1/2 study in CTCL, in which BNZ-1 exhibited a substantial improvement in safety and efficacy relative to standard of care. BNZ-1 has orphan drug designation in US and EU.

For our latest CTCL trial information, please refer to our entries on clinicaltrials.gov. More about our data is available at this link.

BNZ-1 (IL-2/9/15 Inhibitor) for Alopecia Areata

Alopecia areata is an immune mediated hair loss that afflicts more than 500,000 people annually, making it amongst the most common autoimmune disorders in the U.S. with 40% of patients under age 18. There is no FDA approved therapy for alopecia areata, and treatment is limited to the use of topical or intralesional injections of steroids. Current understanding of the etiology of alopecia areata suggests a substantial role for IL-2, IL-9, and IL-15 in the immune dysregulation that increases T-cell proliferation following the initial loss of immune privilege in and around hair follicles, and that results in attacks on the follicular system by cytotoxic CD8 cells.

Since the discovery of IL-2, IL-15, and IFN-γ as key drivers of alopecia pathology, JAK inhibitors have been used in lieu of molecules with more targeted mechanisms. Their modest efficacy has proven the relevance of the JAK pathway to the manifestation of the disease, but as in other use-cases, their broad inhibition retains off target effects. Nonetheless, the JAK pathway is important in the context of BNZ-1 since it is one out of three downstream pathways to IL-2, IL-9, and IL-15 signaling. Modulation of IL-2 and IL-15 will also indirectly regulate IFN-γ as well. Therefore, complete inhibition of these cytokines by BNZ-1 should elicit a more potent blockade of cytokine signaling. This hypothesis was confirmed by our preclinical studies since treatment with BNZ-1 resulted in a substantial decrease in cytotoxic CD8 T-cell activation, reduced numbers of activated cytotoxic CD8 cells around the hair follicles, and durably reversed hair loss. We believe the unique ability of BNZ-1 to selectively and completely inhibit each of the cytokines implicated in disease pathology is necessary for the successful treatment of alopecia areata, and our data generated to date provide strong rationale to commence a Phase 2 trial.

BNZ-2 (IL-15/21 Inhibitor) for Inflammatory Diseases of the GI Tract

BNZ-2 is also an inhibitor of members of the IL-2 family. It is a Phase 1 ready selective inhibitor of IL-15 and IL-21. A growing body of evidence implicates IL-15 and IL-21 in a number of inflammatory diseases of the GI tract including celiac disease, IBD, Type I diabetes, and NASH, providing a strong rationale for applicability of BNZ-2 in these diseases.

In preclinical toxicology studies, BNZ-2 treatment resulted in a dose-dependent decrease of both B-cells and CD8-effector cells, indicating the inhibition of both IL-15 and IL-21. Furthermore, BNZ-2 was shown to completely protect the integrity of the gut in an animal model of GI tract inflammation and to prevent a key disease burden, infiltration of lymphocytes to the gut epithelial layer.

BNZ-3 (IL-15/21 Inhibitor), Oral Administration

BNZ-3 is an inhibitor of IL-15 and IL-21 that is designed for an oral route of administration. BNZ-3 retains the same binding motifs to inhibit IL-15 and IL-21 as BNZ-2, while remaining stable in stomach and intestinal fluid. An oral formulation that retains efficacy could substantially increase the addressable market for IL-15/IL-21 inhibitors, particularly in immune mediated diseases of the GI tract. BNZ-3 is also the template for our future efforts to create additional multi-cytokine inhibitors that can be delivered orally.

Future Directions

We intend to build on our leadership in developing selective multi-cytokine inhibitors for the IL-2 family and to expand to other families of cytokines. Ultimately, we believe we can create customizable multi-cytokine therapies to target different combinations of cytokines implicated in any immune mediated disease so that we can treat an increasingly complex set of currently untreatable, complex immune disorders and conditions.